JP2011500685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500685A5 JP2011500685A5 JP2010529960A JP2010529960A JP2011500685A5 JP 2011500685 A5 JP2011500685 A5 JP 2011500685A5 JP 2010529960 A JP2010529960 A JP 2010529960A JP 2010529960 A JP2010529960 A JP 2010529960A JP 2011500685 A5 JP2011500685 A5 JP 2011500685A5
- Authority
- JP
- Japan
- Prior art keywords
- ring
- composition
- substituted
- compound
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 53
- 229910052736 halogen Inorganic materials 0.000 claims description 52
- 150000002367 halogens Chemical group 0.000 claims description 52
- 125000001931 aliphatic group Chemical group 0.000 claims description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 41
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 38
- 208000035475 disorder Diseases 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 34
- 229910052717 sulfur Inorganic materials 0.000 claims description 34
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 32
- 239000001257 hydrogen Substances 0.000 claims description 32
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 32
- 239000001301 oxygen Substances 0.000 claims description 32
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 28
- 239000011593 sulfur Substances 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 27
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 24
- 101150065749 Churc1 gene Proteins 0.000 claims description 24
- 102100038239 Protein Churchill Human genes 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 24
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 12
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 12
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 12
- 230000001404 mediated effect Effects 0.000 claims description 11
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 claims description 10
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 239000012472 biological sample Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 102000001253 Protein Kinase Human genes 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000002761 neurofibromatosis 2 Diseases 0.000 claims description 4
- -1 propylene- Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000019838 Blood disease Diseases 0.000 claims description 2
- 208000020084 Bone disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000009424 thromboembolic effect Effects 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 30
- 0 *c1cccc(NC2=CC(Nc3cc(NC(C=C)=O)ccc3)=NCN2)c1 Chemical compound *c1cccc(NC2=CC(Nc3cc(NC(C=C)=O)ccc3)=NCN2)c1 0.000 description 13
- NCFLMBPNYFEFKD-UHFFFAOYSA-N N#CC1(CC1)C(Nc1cccc(Nc2ncnc(Nc(cc3)cc(Cl)c3F)c2)c1)=O Chemical compound N#CC1(CC1)C(Nc1cccc(Nc2ncnc(Nc(cc3)cc(Cl)c3F)c2)c1)=O NCFLMBPNYFEFKD-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- ZBVCFJYVESEWGO-UHFFFAOYSA-N C#CC(C1)C=CC=C1Nc1ncnc(Nc2cccc(C#C)c2)c1 Chemical compound C#CC(C1)C=CC=C1Nc1ncnc(Nc2cccc(C#C)c2)c1 ZBVCFJYVESEWGO-UHFFFAOYSA-N 0.000 description 1
- VMUSSBBJCXBDBU-UHFFFAOYSA-N C=CC(N(C1)C=CC1Nc1ncnc(Nc(cc2)ccc2Oc2ccccc2)c1)=O Chemical compound C=CC(N(C1)C=CC1Nc1ncnc(Nc(cc2)ccc2Oc2ccccc2)c1)=O VMUSSBBJCXBDBU-UHFFFAOYSA-N 0.000 description 1
- WNVGOSPWYUICTQ-UHFFFAOYSA-N C=CC(N(CCC1)CC1Nc1cc(Nc(cc2)ccc2Oc2ccccc2)ncn1)=O Chemical compound C=CC(N(CCC1)CC1Nc1cc(Nc(cc2)ccc2Oc2ccccc2)ncn1)=O WNVGOSPWYUICTQ-UHFFFAOYSA-N 0.000 description 1
- RQRPPTFYXPRMQJ-WSDLNYQXSA-N C=CC(Nc1cc(N/C(/N=C\N)=C/CCCN(CC2)c3c2cccc3)ccc1)=O Chemical compound C=CC(Nc1cc(N/C(/N=C\N)=C/CCCN(CC2)c3c2cccc3)ccc1)=O RQRPPTFYXPRMQJ-WSDLNYQXSA-N 0.000 description 1
- TVZJFXDFZGMEPL-UHFFFAOYSA-N C=CC(Nc1cc(Nc2ncnc(Oc3cc(C(F)(F)F)ccc3)c2)ccc1)=O Chemical compound C=CC(Nc1cc(Nc2ncnc(Oc3cc(C(F)(F)F)ccc3)c2)ccc1)=O TVZJFXDFZGMEPL-UHFFFAOYSA-N 0.000 description 1
- RNTKTHMANBLYCF-UHFFFAOYSA-N C=CC(Nc1cccc(Nc2cc(Oc(cc3)ccc3Oc3ccccc3)ncn2)n1)=O Chemical compound C=CC(Nc1cccc(Nc2cc(Oc(cc3)ccc3Oc3ccccc3)ncn2)n1)=O RNTKTHMANBLYCF-UHFFFAOYSA-N 0.000 description 1
- BUQSZIWLZKNBLC-UHFFFAOYSA-N C=CC(Nc1cccc(Nc2ncnc(Nc(cc3)cc(C4CC4)c3OCC3=CC(F)=CCC3)c2)c1)=O Chemical compound C=CC(Nc1cccc(Nc2ncnc(Nc(cc3)cc(C4CC4)c3OCC3=CC(F)=CCC3)c2)c1)=O BUQSZIWLZKNBLC-UHFFFAOYSA-N 0.000 description 1
- BPGCSHREUPSOBZ-UHFFFAOYSA-N C=CS(Nc1cccc(Nc2ncnc(OC(C=CC3)=CC3C(F)(F)F)c2)c1)(=O)=O Chemical compound C=CS(Nc1cccc(Nc2ncnc(OC(C=CC3)=CC3C(F)(F)F)c2)c1)(=O)=O BPGCSHREUPSOBZ-UHFFFAOYSA-N 0.000 description 1
- DVLDHCKDNMHWQB-UHFFFAOYSA-N CC(C(c1cccc(Nc2ncnc(Nc(cc3)ccc3Oc3ccccc3)c2)c1)=O)=C Chemical compound CC(C(c1cccc(Nc2ncnc(Nc(cc3)ccc3Oc3ccccc3)c2)c1)=O)=C DVLDHCKDNMHWQB-UHFFFAOYSA-N 0.000 description 1
- KWMYVFPDXNCCKH-UHFFFAOYSA-N CC(C)=CC(c1cccc(Nc2ncnc(Nc(cc3)ccc3Oc3ccccc3)c2)c1)=O Chemical compound CC(C)=CC(c1cccc(Nc2ncnc(Nc(cc3)ccc3Oc3ccccc3)c2)c1)=O KWMYVFPDXNCCKH-UHFFFAOYSA-N 0.000 description 1
- DBHFVPQUYSHLFK-UHFFFAOYSA-N CN(C(C=C)=O)c1cccc(Nc2cc(Nc(cc3Cl)ccc3F)ncn2)c1 Chemical compound CN(C(C=C)=O)c1cccc(Nc2cc(Nc(cc3Cl)ccc3F)ncn2)c1 DBHFVPQUYSHLFK-UHFFFAOYSA-N 0.000 description 1
- LTASRTYKQQODNV-VMPITWQZSA-N CN(C)C/C=C/C(N(C)c1cc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)ccc1)=O Chemical compound CN(C)C/C=C/C(N(C)c1cc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)ccc1)=O LTASRTYKQQODNV-VMPITWQZSA-N 0.000 description 1
- XNOSGIQEBKFECM-BJMVGYQFSA-N CN(C)C/C=C/C(Nc1cccc(Nc2cc(Nc(cc3)cc(Cl)c3OCc3cc(F)ccc3)ncn2)c1)=O Chemical compound CN(C)C/C=C/C(Nc1cccc(Nc2cc(Nc(cc3)cc(Cl)c3OCc3cc(F)ccc3)ncn2)c1)=O XNOSGIQEBKFECM-BJMVGYQFSA-N 0.000 description 1
- PZTOMZJQXJFNPK-QPJJXVBHSA-N CN(C)C/C=C/C(Nc1cccc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)n1)=O Chemical compound CN(C)C/C=C/C(Nc1cccc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)n1)=O PZTOMZJQXJFNPK-QPJJXVBHSA-N 0.000 description 1
- KEBFJKIAGQTKMY-UHFFFAOYSA-N CN(c1ccccc1)c1cc(Nc2cc(NC(C=C)=O)ccc2)ccn1 Chemical compound CN(c1ccccc1)c1cc(Nc2cc(NC(C=C)=O)ccc2)ccn1 KEBFJKIAGQTKMY-UHFFFAOYSA-N 0.000 description 1
- ZBNNJYMQAROQAO-SNAWJCMRSA-N Cc(ccc(NC(/C=C/CN(C)C)=O)c1)c1Nc1ncnc(Nc(cc2Cl)ccc2F)c1 Chemical compound Cc(ccc(NC(/C=C/CN(C)C)=O)c1)c1Nc1ncnc(Nc(cc2Cl)ccc2F)c1 ZBNNJYMQAROQAO-SNAWJCMRSA-N 0.000 description 1
- PBKRZTJKEIMCGU-UHFFFAOYSA-N O=C(C1(CC1)S=O)Nc1cc(Nc2cc(NC(CC3)=CC(Cl)=C3OCc3ccccn3)ncn2)ccc1 Chemical compound O=C(C1(CC1)S=O)Nc1cc(Nc2cc(NC(CC3)=CC(Cl)=C3OCc3ccccn3)ncn2)ccc1 PBKRZTJKEIMCGU-UHFFFAOYSA-N 0.000 description 1
- HPIAUZVKQHGXGR-UHFFFAOYSA-N O=C(C1(CC1)S=O)Nc1cccc(Nc2ncnc(Nc(cc3)cc(Cl)c3F)c2)c1 Chemical compound O=C(C1(CC1)S=O)Nc1cccc(Nc2ncnc(Nc(cc3)cc(Cl)c3F)c2)c1 HPIAUZVKQHGXGR-UHFFFAOYSA-N 0.000 description 1
- XRNZNVGHFYMJHD-UHFFFAOYSA-N O=C(CCl)Nc1cccc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)c1 Chemical compound O=C(CCl)Nc1cccc(Nc2ncnc(Nc(cc3Cl)ccc3F)c2)c1 XRNZNVGHFYMJHD-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98143207P | 2007-10-19 | 2007-10-19 | |
| US60/981,432 | 2007-10-19 | ||
| US5200208P | 2008-05-09 | 2008-05-09 | |
| US61/052,002 | 2008-05-09 | ||
| PCT/US2008/011911 WO2009051822A1 (en) | 2007-10-19 | 2008-10-17 | Heteroaryl compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014112633A Division JP2014156489A (ja) | 2007-10-19 | 2014-05-30 | ヘテロアリール化合物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500685A JP2011500685A (ja) | 2011-01-06 |
| JP2011500685A5 true JP2011500685A5 (https=) | 2012-11-22 |
| JP5600063B2 JP5600063B2 (ja) | 2014-10-01 |
Family
ID=40567710
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529960A Expired - Fee Related JP5600063B2 (ja) | 2007-10-19 | 2008-10-17 | ヘテロアリール化合物およびその使用 |
| JP2014112633A Pending JP2014156489A (ja) | 2007-10-19 | 2014-05-30 | ヘテロアリール化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014112633A Pending JP2014156489A (ja) | 2007-10-19 | 2014-05-30 | ヘテロアリール化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US7982036B2 (https=) |
| EP (1) | EP2214486A4 (https=) |
| JP (2) | JP5600063B2 (https=) |
| CN (2) | CN105367503A (https=) |
| AU (3) | AU2008314632B2 (https=) |
| CA (2) | CA2920996A1 (https=) |
| TW (2) | TWI475996B (https=) |
| WO (1) | WO2009051822A1 (https=) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US7989465B2 (en) * | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| CN105367503A (zh) | 2007-10-19 | 2016-03-02 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| PT2300013T (pt) | 2008-05-21 | 2017-10-31 | Ariad Pharma Inc | Derivados de fósforo como inibidores de cinases |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| ES2660418T3 (es) | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
| JP2012501654A (ja) * | 2008-09-05 | 2012-01-26 | アビラ セラピューティクス， インコーポレイテッド | 不可逆的インヒビターの設計のためのアルゴリズム |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| AR077033A1 (es) | 2009-06-11 | 2011-07-27 | Hoffmann La Roche | Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| WO2011017296A1 (en) * | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| NZ620174A (en) * | 2009-09-16 | 2016-08-26 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
| MX2012004373A (es) * | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| EP2519664A4 (en) | 2009-12-30 | 2014-03-12 | Avila Therapeutics Inc | LIGAND-RELATED COVALENTS MODIFYING A PROTEIN |
| JP2013517273A (ja) * | 2010-01-13 | 2013-05-16 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 化合物および方法 |
| US8927547B2 (en) | 2010-05-21 | 2015-01-06 | Noviga Research Ab | Pyrimidine derivatives |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| CN105566229A (zh) | 2010-08-10 | 2016-05-11 | 西建阿维拉米斯研究公司 | Btk抑制剂的苯磺酸盐及其用途和制备方法 |
| EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| MX382354B (es) | 2010-11-01 | 2025-03-13 | Celgene Car Llc | Compuestos heterocíclicos y usos de los mismos. |
| JP5957003B2 (ja) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | 変異体選択的ｅｇｆｒ阻害剤およびその使用 |
| DK2688883T3 (en) | 2011-03-24 | 2016-09-05 | Noviga Res Ab | pyrimidine |
| US9834518B2 (en) | 2011-05-04 | 2017-12-05 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| KR20180084153A (ko) * | 2011-06-10 | 2018-07-24 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법 |
| CN103702990B (zh) | 2011-07-27 | 2015-09-09 | 阿斯利康(瑞典)有限公司 | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 |
| AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| CA2861010A1 (en) | 2012-01-13 | 2013-07-18 | Xiao Xu | Heterocyclic compounds and uses as anticancer agents |
| US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| PL2805940T3 (pl) | 2012-01-17 | 2017-06-30 | Astellas Pharma Inc. | Związek pirazynokarboksyamidowy |
| PL2825042T3 (pl) | 2012-03-15 | 2019-02-28 | Celgene Car Llc | Sole inhibitora kinazy receptora czynnika wzrostu naskórka |
| KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
| EP2833886B1 (en) | 2012-04-04 | 2020-08-12 | HangzhouDeRenYuCheng Biotechnology Ltd. | Substituted quinolines as bruton's tyrosine kinase inhibitors |
| WO2013161848A1 (ja) * | 2012-04-27 | 2013-10-31 | カルナバイオサイエンス株式会社 | 新規１，２，４－トリアジン誘導体 |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| WO2013173518A1 (en) * | 2012-05-16 | 2013-11-21 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| JO3754B1 (ar) | 2012-06-04 | 2021-01-31 | Pharmacyclics Llc | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| US9714450B2 (en) | 2012-08-31 | 2017-07-25 | New York University | Methods for diagnosing and treating schizophrenia |
| CN104583195B (zh) * | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| EA201590855A1 (ru) | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| US9126950B2 (en) | 2012-12-21 | 2015-09-08 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| AU2014214846A1 (en) | 2013-02-08 | 2015-07-23 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| HRP20170217T1 (hr) | 2013-04-25 | 2017-04-21 | Beigene, Ltd. | Fuzinirani heterociklički spojevi kao inhibitori protein kinaze |
| WO2014187319A1 (en) | 2013-05-21 | 2014-11-27 | Jiangsu Medolution Ltd | Substituted pyrazolopyrimidines as kinases inhibitors |
| NZ715687A (en) | 2013-07-11 | 2019-04-26 | Acea Biosciences Inc | Pyrimidine derivatives as kinase inhibitors |
| CA2919996A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
| KR101665301B1 (ko) | 2013-08-07 | 2016-10-11 | 카딜라 핼쓰캐어 리미티드 | 야누스 키나제의 억제제로서 n-시아노메틸아미드 |
| US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
| ES2792979T3 (es) | 2013-08-22 | 2020-11-12 | Jubilant Biosys Ltd | Compuestos de pirimidina sustituidos, composiciones y aplicaciones médicas de los mismos |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| BR112016008632A8 (pt) * | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| US9795604B2 (en) | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| US9856223B2 (en) * | 2013-12-13 | 2018-01-02 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| SG11201700849XA (en) | 2014-08-07 | 2017-03-30 | Pharmacyclics Llc | Novel formulations of a bruton's tyrosine kinase inhibitor |
| US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
| WO2016029839A1 (zh) * | 2014-08-25 | 2016-03-03 | 四川海思科制药有限公司 | 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途 |
| CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| CN104860890B (zh) * | 2015-04-29 | 2018-03-13 | 上海泓博智源医药股份有限公司 | T790m突变型egfr的抑制剂及其在制备抗肿瘤药物中的应用 |
| JP6863901B2 (ja) * | 2015-05-13 | 2021-04-28 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| AU2016317049A1 (en) | 2015-08-31 | 2018-03-15 | Pharmacyclics Llc | BTK inhibitor combinations for treating multiple myeloma |
| KR20180067584A (ko) | 2015-10-09 | 2018-06-20 | 아세아 테라퓨틱스 인코포레이티드 | 피롤로피리미딘 키나아제 억제제의 약학적 염, 물리적 형태 및 조성물, 및 이들의 제조 방법 |
| AU2016379292B2 (en) | 2015-12-24 | 2021-03-25 | Kyowa Kirin Co., Ltd. | α, β unsaturated amide compound |
| CN106928150B (zh) * | 2015-12-31 | 2020-07-31 | 恩瑞生物医药科技（上海）有限公司 | 丙烯酰胺苯胺衍生物及其药学上的应用 |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| CA3033827A1 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof |
| PT3500299T (pt) | 2016-08-19 | 2024-02-21 | Beigene Switzerland Gmbh | Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro |
| CN109982687A (zh) | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| AU2017355544A1 (en) | 2016-11-03 | 2019-05-16 | Juno Therapeutics, Inc. | Combination therapy of a T cell therapy and a BTK inhibitor |
| CN106749042B (zh) * | 2016-11-16 | 2019-01-22 | 大连医科大学 | 磺酰胺基嘧啶类化合物，组合物及用途 |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| AU2017408099A1 (en) | 2017-04-07 | 2019-11-07 | ACEA Therapeutics, Inc. | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| WO2018235926A1 (ja) | 2017-06-23 | 2018-12-27 | 協和発酵キリン株式会社 | α、β不飽和アミド化合物 |
| TW202515616A (zh) | 2017-06-26 | 2025-04-16 | 英屬開曼群島商百濟神州有限公司 | 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| JP2019062834A (ja) * | 2017-10-03 | 2019-04-25 | アークレイ株式会社 | ヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異検出用プローブ、ヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異検出用キット、及びヒトｅｇｆｒのｃ７９７ｓ（ｇ２３９０ｃ）変異の検出方法 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| US20210121466A1 (en) | 2018-05-03 | 2021-04-29 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| WO2020249001A1 (zh) | 2019-06-10 | 2020-12-17 | 百济神州瑞士有限责任公司 | 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法 |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| AU2022321449B2 (en) * | 2021-08-02 | 2025-02-20 | Abbisko Therapeutics Co., Ltd. | Pyrimidine-4,6-diamine derivative, a preparation method therefor, and a pharmaceutical application thereof |
| TW202317106A (zh) * | 2021-08-27 | 2023-05-01 | 南韓商柳韓洋行 | 作為egfr抑制劑之取代胺基吡啶化合物 |
| CN114621922A (zh) * | 2022-02-15 | 2022-06-14 | 中山大学附属第五医院 | 一种大鼠海绵体神经来源施旺细胞的提取纯化和培养方法 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
| CN120359217A (zh) * | 2022-09-15 | 2025-07-22 | 上海睿跃生物科技有限公司 | 经修饰的蛋白质以及蛋白质结合剂和降解剂 |
| CN116444728B (zh) * | 2023-04-20 | 2025-02-28 | 浙江南洋华诚科技股份有限公司 | 一种风电电容器高耐压高耐温薄膜及其制备方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0741461A (ja) | 1993-05-27 | 1995-02-10 | Eisai Co Ltd | スルホン酸エステル誘導体 |
| GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| US5977117A (en) * | 1996-01-05 | 1999-11-02 | Texas Biotechnology Corporation | Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin |
| US5994375A (en) * | 1996-02-12 | 1999-11-30 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants |
| BRPI9909191B8 (pt) * | 1998-03-27 | 2021-07-06 | Janssen Pharmaceutica Nv | derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende |
| CZ299380B6 (cs) | 1998-03-27 | 2008-07-09 | Janssen Pharmaceutica N. V. | Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující |
| US6303652B1 (en) * | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| US6632820B1 (en) * | 1998-08-29 | 2003-10-14 | Astrazeneca Ab | Pyrimidine compounds |
| US6262088B1 (en) * | 1998-11-19 | 2001-07-17 | Berlex Laboratories, Inc. | Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| WO2000071536A1 (en) | 1999-05-20 | 2000-11-30 | E.I. Du Pont De Nemours And Company | Heteroaryloxypyrimidine insecticides and acaricides |
| CA2384188C (en) * | 1999-09-24 | 2008-06-17 | Janssen Pharmaceutica N.V. | Antiviral compositions |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| EE200200426A (et) * | 2000-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid |
| CA2417500C (en) | 2000-07-28 | 2008-11-18 | Georgetown University Medical Center | Erbb-2 selective small molecule kinase inhibitors |
| US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| MXPA04004178A (es) * | 2001-11-01 | 2004-09-06 | Janssen Pharmaceutica Nv | Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta. |
| KR20040062557A (ko) * | 2001-11-01 | 2004-07-07 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체 |
| US7589105B2 (en) * | 2001-11-28 | 2009-09-15 | Btg International Limited | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound |
| AR039540A1 (es) | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
| US6841664B2 (en) | 2002-07-25 | 2005-01-11 | Enanra Pharmaceuticals, Inc. | 6,11-4-carbon bridged ketolides |
| TW200406374A (en) * | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| DE10226943A1 (de) * | 2002-06-17 | 2004-01-08 | Bayer Ag | Phenylaminopyrimidine und ihre Verwendung |
| US20040002395A1 (en) * | 2002-06-27 | 2004-01-01 | Poynor Raymond L. | Bridge weight for metal wood golf club |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| AU2002951853A0 (en) | 2002-10-04 | 2002-10-24 | Commonwealth Scientific And Industrial Research Organisation | Crystal structure of erbb2 and uses thereof |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| JP2006522589A (ja) | 2003-04-07 | 2006-10-05 | プレーシス ファーマスーティカルズ インコーポレイテッド | 被験体の細胞において生物学的標的を不活性化する試験化合物の能力を測定する方法 |
| CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| JPWO2005040135A1 (ja) * | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
| JP2007515400A (ja) * | 2003-11-28 | 2007-06-14 | ノバルティス アクチエンゲゼルシャフト | タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体 |
| NZ546058A (en) * | 2004-01-12 | 2010-09-30 | Ym Biosciences Australia Pty | Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors |
| US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
| EP1763526B1 (en) * | 2004-06-28 | 2009-06-24 | Bayer Schering Pharma AG | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors |
| WO2006045066A2 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
| MY169441A (en) | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| WO2006128172A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| US8076343B2 (en) * | 2005-07-26 | 2011-12-13 | Vertex Pharmaceuticals Incorporated | Benzimidazoles useful as inhibitors of protein kinases |
| JP2009514876A (ja) * | 2005-11-03 | 2009-04-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼのための化合物および組成物 |
| WO2007081630A2 (en) | 2005-12-21 | 2007-07-19 | Janssen Pharmaceutica, N.V. | Substituted pyrimidinyl kinase inhibitors |
| KR20080110998A (ko) | 2006-01-30 | 2008-12-22 | 엑셀리시스, 인코포레이티드 | Ｊａｋ２ 조절자로서 ４아릴２아미노피리미딘 또는 4아릴２아미노알킬피리미딘 및 이들을 포함하는 약제학적 조성물 |
| US7560588B2 (en) | 2006-04-27 | 2009-07-14 | Intezyne Technologies, Inc. | Poly(ethylene glycol) containing chemically disparate endgroups |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| CA2668286C (en) | 2006-11-03 | 2014-09-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| US8846704B2 (en) | 2007-01-31 | 2014-09-30 | YM Biosciences Austraila Pty Ltd | Thiopyrimidine-based compounds and uses thereof |
| EP2014657A1 (de) * | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| CN105367503A (zh) | 2007-10-19 | 2016-03-02 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
| TWI546290B (zh) | 2008-06-27 | 2016-08-21 | 賽基艾維洛米斯研究股份有限公司 | 雜芳基化合物及其用途 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
-
2008
- 2008-10-17 CN CN201510792304.0A patent/CN105367503A/zh active Pending
- 2008-10-17 JP JP2010529960A patent/JP5600063B2/ja not_active Expired - Fee Related
- 2008-10-17 TW TW097139912A patent/TWI475996B/zh not_active IP Right Cessation
- 2008-10-17 AU AU2008314632A patent/AU2008314632B2/en not_active Ceased
- 2008-10-17 CA CA2920996A patent/CA2920996A1/en not_active Abandoned
- 2008-10-17 EP EP08839939A patent/EP2214486A4/en not_active Withdrawn
- 2008-10-17 TW TW103145233A patent/TWI552752B/zh not_active IP Right Cessation
- 2008-10-17 WO PCT/US2008/011911 patent/WO2009051822A1/en not_active Ceased
- 2008-10-17 CN CN200880121536.1A patent/CN101902911B/zh not_active Expired - Fee Related
- 2008-10-17 CA CA2702674A patent/CA2702674C/en not_active Expired - Fee Related
- 2008-10-17 US US12/253,424 patent/US7982036B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/018,624 patent/US8445498B2/en not_active Expired - Fee Related
-
2013
- 2013-05-02 US US13/875,755 patent/US9040541B2/en not_active Expired - Fee Related
-
2014
- 2014-05-30 JP JP2014112633A patent/JP2014156489A/ja active Pending
-
2015
- 2015-04-22 US US14/693,489 patent/US9393246B2/en not_active Expired - Fee Related
- 2015-05-18 AU AU2015202675A patent/AU2015202675B2/en not_active Expired - Fee Related
-
2016
- 2016-07-12 US US15/208,368 patent/US20160311780A1/en not_active Abandoned
- 2016-11-10 AU AU2016256754A patent/AU2016256754A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500685A5 (https=) | ||
| JP2013515786A5 (https=) | ||
| ES2966917T3 (es) | Nuevo derivado de pirimidina que tiene el efecto de inhibir el crecimiento de células cancerosas y composición farmacéutica que contiene el mismo | |
| ES2928169T3 (es) | Derivados de 4-(3H-indol-5-il)-N-(piridin-2-il)pirimidin-2-amina como inhibidores de proteína cinasa, y método de preparación y uso médico de los mismos | |
| US10570141B2 (en) | Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof | |
| AU2016245864C1 (en) | Substituted quinazoline compounds and methods of use thereof | |
| JP6678655B2 (ja) | Ｒａｆキナーゼ阻害剤としての化合物および組成物 | |
| Eldehna et al. | Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII | |
| AU2012239791B2 (en) | Protein kinase inhibitors | |
| JP2021522275A (ja) | サイクリン依存性キナーゼ阻害剤としての２−アミノ−ピリジンまたは２−アミノ−ピリミジン誘導体 | |
| JP2008528467A5 (https=) | ||
| JP2018526413A5 (https=) | ||
| JP2017511360A5 (https=) | ||
| JP2016519673A5 (https=) | ||
| CY1115171T1 (el) | Ιατρικο φαρμακο | |
| JP6804540B2 (ja) | スルファミド誘導体およびその製造方法と応用 | |
| CN116162087A (zh) | 一种hpk 1和/或lck激酶调节剂、制备方法及其应用 | |
| JP2020506895A5 (https=) | ||
| CA3238572A1 (en) | Selective parp1 inhibitor and application thereof | |
| EP3492469A1 (en) | Compound as selective jak inhibitor, and salt and therapeutic use thereof | |
| RU2015113597A (ru) | Производные аминоизохинолина в качестве ингибиторов протеинкиназы | |
| US9340491B2 (en) | Nitrile derivatives and their pharmaceutical use and compositions | |
| ES2958528T3 (es) | Macrociclos sustituidos útiles como inhibidores de quinasas | |
| US20240051940A1 (en) | Sulfonamides with egfr inhibition activities and their use thereof | |
| ES2969546T3 (es) | Técnica de combiterapia para el agente inhibidor de Axl y el inhibidor de la tirosina··cinasa del EGFR |